Registry of Thrombosis & NEoplasia of Sociedad Española de Oncología Médica

Observational Epidemiological Study of Cancer-associated Thrombosis: Registry of Thrombosis & NEoplasia of SEOM (TESEO Study)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03855592

Acronym

TESEO

Enrollment

700

Registered

2019-02-27

Start date

2018-07-04

Completion date

2026-07-31

Last updated

2025-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Thromboembolism

Brief summary

Epidemiological, observational, non-interventional, multicentric study on patients diagnosed with cancer who develop a venous or arterial thromboembolic episode, symptomatic or incidental, within a month prior to cancer diagnosis or at anytime after such diagnosis

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Over 18 years of age with a histologically confirmed diagnosis of malignant tumor. * Venous or arterial thromboembolism episode, symptomatic or incidental, in the month prior or any time after the cancer diagnosis and in the three previous months to enrollment, confirmed with an imaging technique: Doppler echocardiography, computed tomography (CT) angiography, etc. * Signing of informed consent.

Exclusion criteria

* Clinical diagnosis of thromboembolic event without radiological confirmation. * Presenting a single episode of superficial thrombophlebitis without association with another thromboembolic event. * Each patient will be recorded just once, and therefore a second thromboembolic event will be considered a rethrombosis and will be recorded as such. Patients with a rethrombosis and a previous thromboembolic event before the start of the study in each center will not be able to be included.

Design outcomes

Primary

Measure	Time frame	Description
Location of origin of the thromboembolytic event	Baseline	Distribution in the number of patients according to the anatomical location affected by the thromboembolytic event.
Vessel of origin of the thromboembolytic event	Baseline	Distribution in the number of patients according to the type of vessel affected by the thromboembolytic event.
Thromboembolytic event diagnosis type	Baseline	Proportion of patients with incidental versus symptomatic thormboembolic events
Primary tumor at the time of the thromboembolic event	Baseline	Distribution of patients according to the organ affected by the primary tumor.
Tumor-Node-Metastasis classification	Baseline	Based on the American Joint Committee on Cancer 2018 Tumor-Node-Metastasis classification system: T for extent or size of the tumor, N for lymph nodes spread and M for metastasis.
Time between cancer diagnosis and thromboembolic event	Baseline	Based on date on confirmed diagnosis of cancer (primary tumor) and date of thromboembolic event
Patient situation at the last visit	12 months	Number of patients with rethrombosis, bleeding, other complications, tumor progression or death.
Characteristics of treatment administered for cancer	Baseline	Based on the number of patients prescribed with chemotherapy, radiation therapy, hormonal therapy, erythropoietin, transfusions, surgery, catheter, etc.

Countries

Spain

Contacts

Primary ContactAndres Muñoz, M.D.

investigacion@mfar.net+34 93 434 44 12

Backup ContactFederico Nepote